Nephrotic syndrome (NS) is a common childhood kidney disease caused by impaired glomerular function, characterized by protein leakage from the blood to the urine through the glomeruli, resulting in proteinuria, hypoalbuminemia, hypercholesterolemia and generalized oedema. NS is descriptively classified upon the patients’ response to steroid treatment as steroid-sensitive NS (SSNS) or steroid-resistant NS (SRNS). Podocin mutations (NPHS2 gene) are mostly responsible for SRNS of childhood onset (3–5,8,9). The NPHS2 gene lies in the chromosome 1q25–q31 region and encodes a 383-aminoacid protein called podocin. Podocin is an integral membrane protein responsible for nephrin transport to membrane and for podocyte intracellular signalling. The lack of podocin results in extensive podocyte lesions and proteinuria (1,5,9). Podocin mutations are mostly responsible for SRNS of childhood onset (3–5,8,9). The NPHS2 gene lies in the chromosome 1q25–q31 region and encodes a 383-aminoacid protein called podocin. Podocin mutations (NPHS2 gene) are mostly responsible for steroid-resistant nephrotic syndrome (SRNS) of childhood onset. Patients with NPHS2 gene mutations do not respond to corticoids and other immunosuppressive agents; partial remission can be rarely induced by cyclosporin A. We present a boy, where SRNS was diagnosed within first year of life. By the age of 15 years, proteinuria reached 9000 mg/24 h, cholesterolemia 15 mmol/L, albuminemia 19.6 g/L, in spite of combined therapy with cyclosporine A, methylprednisolone, enalapril and losartan. At that time a combined heterozygous form of two NPHS2 gene mutations (p.R138Q and p.V290M) was diagnosed, methylprednisolone was discontinued and patient underwent ten plasmapheresis procedures. This resulted in clinical improvement (proteinuria 3000 mg/24 h, S-cholesterol 6 mmol/L, albumin 30g/L) lasting for three years. In conclusion, plasmapheresis can result in clinical improvement and stabilization of SRNS caused by podocine mutation, before renal replacement therapy is initiated.

**Summary:** Podocin mutations (NPHS2 gene) are mostly responsible for steroid-resistant nephrotic syndrome (SRNS) of childhood onset. Patients with NPHS2 gene mutations do not respond to corticoids and other immunosuppressive agents; partial remission can be rarely induced by cyclosporin A. We present a boy, where SRNS was diagnosed within first year of life. By the age of 15 years, proteinuria reached 9000 mg/24 h, cholesterolemia 15 mmol/L, albuminemia 19.6 g/L, in spite of combined therapy with cyclosporine A, methylprednisolone, enalapril and losartan. At that time a combined heterozygous form of two NPHS2 gene mutations (p.R138Q and p.V290M) was diagnosed, methylprednisolone was discontinued and patient underwent ten plasmapheresis procedures. This resulted in clinical improvement (proteinuria 3000 mg/24 h, S-cholesterol 6 mmol/L, albumin 30g/L) lasting for three years. In conclusion, plasmapheresis can result in clinical improvement and stabilization of SRNS caused by podocine mutation, before renal replacement therapy is initiated.

**Key-words:** Podocin; Steroid-resistant nephrotic syndrome; Plasmapheresis

**Introduction**

Nephrotic syndrome (NS) is a common childhood kidney disease caused by impaired glomerular function, characterized by protein leakage from the blood to the urine through the glomeruli, resulting in proteinuria, hypoalbuminemia, hypercholesterolemia and generalised oedema. NS is descriptively classified upon the patients’ response to steroid treatment as steroid-sensitive NS (SSNS) or steroid-resistant NS (SRNS). Podocin mutations (NPHS2 gene) are mostly responsible for SRNS of childhood onset (3–5,8,9). The NPHS2 gene lies in the chromosome 1q25–q31 region and encodes a 383-aminoacid protein called podocin. Podocin is an integral membrane protein responsible for nephrin transport to membrane and for podocyte intracellular signalling. The lack of podocin results in extensive podocyte lesions and proteinuria (1,5,9). Podocin mutations were identified in infants with early onset of SRNS and focal segmental glomerulosclerosis (FSGS), in patients with familial NS with autosomal recessive inheritance and in sporadic SRNS (1,3–5,8,9). FSGS is identified in approximately 7–10% of renal biopsies in children. The incidence of FSGS has increased eleven-fold in two decades: between 1980 and 2000 from 0.2 to 2.3%, respectively (11). Patients with NPHS2 gene mutations do not respond to corticotherapy. The treatment of these patients is mostly symptomatic using antihypertensive drugs with antiproteinuric properties, such as angiotensin-converting enzyme inhibitors and/or angiotensin receptor blockers. Beside partial response to immunosuppression, in particular to cyclosporin A, no cases of complete SRNS remission were described and renal transplantation is the only therapeutic alternative (3,6–9). We present a patient with SRNS where plasmapheresis induced clinical improvement lasting for three years.

**Case Report**

A 5-month old boy presented with proteinuria (1000 mg/1 m²/24 hours), microscopic hematuria and hypoalbuminemia suggestive of NS. Corticotherapy (prednisone 60 mg/m² divided into 3 doses/day for 6 weeks, followed by 40 mg/m² as a single morning dose on alternate days for the next 6 weeks) together with levamizol and ketotifen had no effect, confirming the diagnosis of SRNS. First renal biopsy was performed at 4.5 years of age and histologic evaluation revealed FSGS. Cyclophosphamide (2.5 mg/kg/day) and prednisone (0.75 mg/kg/day) treatment in the following
the plasmapheresis termination the patient had no oedema in hypercholesterolemia to 6 mmol/L. Six months after plasmapheresis cycle. Plasma exchanges resulted in drop the patient remained stable throughout the therapeutic procedures in 16 days. There were no adverse reactions. Therefore, the patient underwent 10 plasma exchange procedures on a daily basis for the first four days, followed by six procedures every other day. Therefore, the patient underwent 10 plasma exchange procedures in 16 days. There were no adverse reactions. Concerning the cardiovascular and respiratory system, the patient remained stable throughout the therapeutic plasmapheresis cycle. Plasma exchanges resulted in drop in hypercholesterolemia to 6 mmol/L. Six months after the plasmapheresis termination the patient had no oedema, proteinuria was ~3000 mg/24 hours, S-cholesterol 6 mmol/L, albumin 30 g/L, creatinine clearance 1.456 mL/s/1.73 m². Cyclosporin A was discontinued after additional 2 months. These findings persisted for 3 years before proteinuria gradually reached 9.6 g/24 hours. Currently, six years after plasmapheresis, the patient is undergoing regular haemodialysis and is on a waiting list for renal transplantation.

Discussion

In our patient, two pathogenic NPHS2 gene mutations, each one segregating from a different parent, were found. Therefore, both maternal and paternal alleles have disease-causing mutation resulting in SRNS. Patients with genetic NS do not respond to corticoids and other immunosuppressive agents. Angiotensin-converting enzyme inhibitors and/or angiotensin receptor blockers are used to decrease blood pressure and proteinuria (6). Partial remission in SRNS can be induced by cyclosporine A (6–8), which was confirmed as superior to cyclophosphamide (7). Cyclosporine A therapy has so far resulted in partial remission in seven patients with NS due to NPHS2 mutations (6–8). It has been proposed that cyclosporine A stabilizes podocyte actin cytoskeleton, resulting in antiproteinuric effect (6). Plasmapheresis has been also reported to be effective in SRNS, as five sessions of plasma exchange induced remission in an eight-year old boy with otherwise therapy-resistant FSGS (10). Circulating glomerular permeability factors derived from T lymphocytes may play a crucial role in the protein excretion of nephrotic syndrome. Circulating glomerular albumin permeability factors were also detected in patients with primary FSGS. Plasma exchange is beneficial in these patients by removing the glomerular permeability factors and lipids. In addition to the removal of pathological agents such as antibodies, immune complexes and/or immune-associated cells, the removal of proinflammatory mediators including cytokines, chemokines and complements, and a demonstrated improvement of immune system have been postulated to contribute to the beneficial effects of apheresis (11). In our patient cyclosporine A did not induce partial remission. It is seems very likely that ten sessions of plasmapheresis significantly contributed to clinical improvement lasting for three years, as previous therapy with cyclosporine A, glucocorticoids, enalapril and losartan had no effect on clinical course of SRNS. The podocin gene should be evaluated in children with SRNS in order to determine further therapeutic strategy, as corticotherapy has no effect and cyclosporine A does not always induce partial remission. Plasmapheresis can result in clinical improvement and stabilization of SRNS caused by podocine mutation, before renal replacement therapy is initiated.

References


Corresponding author:

Sylva Skálová, M.D., Ph.D., Department of Paediatrics, Charles University in Prague, Faculty of Medicine in Hradec Králové, Czech Republic; e-mail: skalova.s@seznam.cz

Received: 25/10/2009.
Accepted in revised form: 17/05/2010.